Some of targeted drugs have been utilized in ESCC, such as Gefitinib3 (an EGFR inhibitor), Dovitinib4 (an FGFR1 inhibitor), and PD-L1 blockers5. Here, CD274 is linked to esophageal squamous cell carcinoma.